| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Candida albicans | 100 | 2023 | 163 | 20.730 |
Why?
|
| Biofilms | 67 | 2023 | 166 | 15.890 |
Why?
|
| Antifungal Agents | 64 | 2023 | 147 | 14.590 |
Why?
|
| Candidiasis | 41 | 2023 | 85 | 8.860 |
Why?
|
| Candida | 22 | 2023 | 32 | 5.760 |
Why?
|
| Fungal Proteins | 38 | 2019 | 130 | 4.550 |
Why?
|
| Microbial Sensitivity Tests | 37 | 2023 | 203 | 3.490 |
Why?
|
| Fluconazole | 28 | 2016 | 41 | 2.910 |
Why?
|
| Hyphae | 12 | 2019 | 36 | 2.570 |
Why?
|
| Gene Expression Regulation, Fungal | 17 | 2019 | 72 | 2.490 |
Why?
|
| Mycoses | 6 | 2020 | 29 | 2.080 |
Why?
|
| Drug Resistance, Fungal | 19 | 2015 | 32 | 1.970 |
Why?
|
| Fungi | 6 | 2020 | 86 | 1.880 |
Why?
|
| Candidiasis, Oral | 15 | 2015 | 23 | 1.810 |
Why?
|
| Echinocandins | 12 | 2013 | 13 | 1.670 |
Why?
|
| Silver | 4 | 2020 | 53 | 1.650 |
Why?
|
| Small Molecule Libraries | 5 | 2017 | 43 | 1.490 |
Why?
|
| Proteomics | 7 | 2014 | 302 | 1.370 |
Why?
|
| Anti-Bacterial Agents | 6 | 2019 | 355 | 1.350 |
Why?
|
| High-Throughput Screening Assays | 8 | 2023 | 63 | 1.310 |
Why?
|
| Virulence | 18 | 2019 | 221 | 1.300 |
Why?
|
| Amphotericin B | 14 | 2013 | 24 | 1.170 |
Why?
|
| Drug Discovery | 4 | 2016 | 77 | 1.100 |
Why?
|
| Antigens, Fungal | 7 | 2006 | 32 | 1.080 |
Why?
|
| Metal Nanoparticles | 4 | 2020 | 180 | 0.960 |
Why?
|
| Fungal Vaccines | 5 | 2020 | 41 | 0.960 |
Why?
|
| Peptides, Cyclic | 5 | 2004 | 30 | 0.950 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 111 | 0.930 |
Why?
|
| Plankton | 5 | 2016 | 12 | 0.870 |
Why?
|
| Mice | 28 | 2023 | 5668 | 0.870 |
Why?
|
| Virulence Factors | 6 | 2019 | 113 | 0.860 |
Why?
|
| Mice, Inbred BALB C | 15 | 2017 | 649 | 0.840 |
Why?
|
| Humans | 65 | 2023 | 34853 | 0.840 |
Why?
|
| Membrane Glycoproteins | 10 | 2008 | 197 | 0.820 |
Why?
|
| Animals | 40 | 2023 | 14307 | 0.770 |
Why?
|
| Disinfectants | 2 | 2020 | 7 | 0.770 |
Why?
|
| Streptococcus gordonii | 1 | 2019 | 2 | 0.720 |
Why?
|
| Microbial Interactions | 1 | 2019 | 10 | 0.710 |
Why?
|
| Lipopeptides | 11 | 2013 | 20 | 0.710 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 74 | 0.700 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 1300 | 0.690 |
Why?
|
| Peptides | 5 | 2004 | 308 | 0.640 |
Why?
|
| Cell Adhesion | 5 | 2019 | 209 | 0.640 |
Why?
|
| Amides | 1 | 2018 | 66 | 0.630 |
Why?
|
| DNA-Binding Proteins | 7 | 2010 | 522 | 0.630 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 600 | 0.620 |
Why?
|
| Auranofin | 2 | 2016 | 2 | 0.620 |
Why?
|
| Benzamides | 1 | 2017 | 76 | 0.610 |
Why?
|
| Cell Wall | 9 | 2013 | 53 | 0.600 |
Why?
|
| Culture Media | 7 | 2010 | 84 | 0.580 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 33 | 0.570 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2016 | 10 | 0.570 |
Why?
|
| Drug Resistance, Microbial | 8 | 2014 | 26 | 0.550 |
Why?
|
| Phosphorylcholine | 1 | 2015 | 8 | 0.550 |
Why?
|
| Bacterial Infections | 1 | 2016 | 44 | 0.550 |
Why?
|
| Transcription Factors | 8 | 2015 | 653 | 0.550 |
Why?
|
| AIDS-Related Opportunistic Infections | 9 | 2005 | 41 | 0.520 |
Why?
|
| Mutation | 14 | 2019 | 1023 | 0.520 |
Why?
|
| Pharyngeal Diseases | 5 | 2002 | 6 | 0.500 |
Why?
|
| Mouth | 4 | 2023 | 44 | 0.470 |
Why?
|
| Carbon Dioxide | 1 | 2013 | 78 | 0.460 |
Why?
|
| Genome, Fungal | 2 | 2019 | 21 | 0.460 |
Why?
|
| Food | 1 | 2013 | 95 | 0.440 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 80 | 0.430 |
Why?
|
| Models, Biological | 5 | 2010 | 642 | 0.430 |
Why?
|
| Endothelial Cells | 3 | 2010 | 296 | 0.430 |
Why?
|
| Denture, Complete, Upper | 2 | 2009 | 2 | 0.420 |
Why?
|
| Catheter-Related Infections | 2 | 2021 | 11 | 0.410 |
Why?
|
| Tetracycline | 1 | 2011 | 17 | 0.410 |
Why?
|
| Neuregulin-1 | 3 | 2016 | 21 | 0.410 |
Why?
|
| Prostheses and Implants | 2 | 2010 | 14 | 0.400 |
Why?
|
| Genetic Engineering | 3 | 2007 | 31 | 0.390 |
Why?
|
| Kidney | 7 | 2011 | 322 | 0.380 |
Why?
|
| Polymethyl Methacrylate | 3 | 2009 | 14 | 0.380 |
Why?
|
| Microbial Viability | 4 | 2018 | 35 | 0.370 |
Why?
|
| Urine | 1 | 2009 | 9 | 0.370 |
Why?
|
| Mycology | 2 | 2011 | 3 | 0.360 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2009 | 19 | 0.350 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 58 | 0.350 |
Why?
|
| Tunicamycin | 1 | 2008 | 23 | 0.340 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2008 | 19 | 0.340 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2017 | 109 | 0.340 |
Why?
|
| Cross Infection | 2 | 2008 | 38 | 0.330 |
Why?
|
| Rheology | 1 | 2008 | 24 | 0.320 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 5 | 2014 | 79 | 0.320 |
Why?
|
| Edetic Acid | 1 | 2007 | 21 | 0.320 |
Why?
|
| Antibodies, Fungal | 4 | 2018 | 23 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 984 | 0.310 |
Why?
|
| Chelating Agents | 1 | 2007 | 53 | 0.310 |
Why?
|
| Drug Synergism | 2 | 2018 | 171 | 0.300 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 136 | 0.300 |
Why?
|
| Equipment and Supplies | 1 | 2006 | 11 | 0.300 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 396 | 0.290 |
Why?
|
| Azoles | 3 | 2011 | 13 | 0.290 |
Why?
|
| Colorimetry | 5 | 2011 | 40 | 0.290 |
Why?
|
| Cryptococcosis | 3 | 2014 | 35 | 0.290 |
Why?
|
| Microscopy, Electron, Scanning | 6 | 2011 | 138 | 0.290 |
Why?
|
| Aspergillus fumigatus | 3 | 2016 | 10 | 0.290 |
Why?
|
| Repressor Proteins | 5 | 2016 | 226 | 0.280 |
Why?
|
| Microscopy, Confocal | 6 | 2011 | 210 | 0.270 |
Why?
|
| HIV Infections | 9 | 2005 | 2207 | 0.270 |
Why?
|
| Stress, Mechanical | 3 | 2010 | 110 | 0.270 |
Why?
|
| Colony Count, Microbial | 5 | 2009 | 66 | 0.260 |
Why?
|
| Female | 20 | 2020 | 19873 | 0.250 |
Why?
|
| Candida glabrata | 2 | 2005 | 5 | 0.250 |
Why?
|
| Cell Survival | 2 | 2017 | 818 | 0.250 |
Why?
|
| Yeasts | 1 | 2003 | 19 | 0.240 |
Why?
|
| Triazoles | 2 | 2003 | 85 | 0.240 |
Why?
|
| Doxycycline | 3 | 2011 | 30 | 0.230 |
Why?
|
| Polystyrenes | 2 | 2001 | 18 | 0.230 |
Why?
|
| Drug Combinations | 3 | 2016 | 89 | 0.230 |
Why?
|
| Pharyngitis | 1 | 2003 | 2 | 0.230 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 2003 | 3 | 0.230 |
Why?
|
| Farnesol | 1 | 2002 | 3 | 0.230 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2013 | 47 | 0.220 |
Why?
|
| Membrane Proteins | 1 | 2006 | 486 | 0.210 |
Why?
|
| Saliva | 2 | 2019 | 97 | 0.210 |
Why?
|
| DNA, Fungal | 5 | 2009 | 40 | 0.210 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2001 | 10 | 0.200 |
Why?
|
| Time Factors | 4 | 2013 | 1681 | 0.200 |
Why?
|
| Epitopes | 4 | 2004 | 145 | 0.200 |
Why?
|
| Stress, Physiological | 2 | 2013 | 137 | 0.200 |
Why?
|
| Denture Cleansers | 2 | 2011 | 2 | 0.200 |
Why?
|
| Chlorhexidine | 2 | 2011 | 4 | 0.200 |
Why?
|
| Vaccines, Combined | 1 | 2020 | 11 | 0.190 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2020 | 11 | 0.190 |
Why?
|
| Lectins, C-Type | 1 | 2020 | 35 | 0.190 |
Why?
|
| Silicones | 1 | 2020 | 7 | 0.190 |
Why?
|
| Elastomers | 1 | 2020 | 3 | 0.190 |
Why?
|
| Bandages | 1 | 2020 | 5 | 0.190 |
Why?
|
| Textiles | 1 | 2020 | 4 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2018 | 392 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 3 | 2011 | 179 | 0.190 |
Why?
|
| Silver Nitrate | 1 | 2019 | 2 | 0.190 |
Why?
|
| Borohydrides | 1 | 2019 | 5 | 0.190 |
Why?
|
| Povidone | 1 | 2019 | 5 | 0.180 |
Why?
|
| Microbiological Techniques | 2 | 2021 | 11 | 0.180 |
Why?
|
| Bacteria | 1 | 2023 | 245 | 0.180 |
Why?
|
| Antigenic Variation | 1 | 1999 | 9 | 0.180 |
Why?
|
| Coccidioides | 1 | 2020 | 51 | 0.180 |
Why?
|
| Down-Regulation | 2 | 2019 | 420 | 0.180 |
Why?
|
| Coccidioidomycosis | 1 | 2020 | 46 | 0.180 |
Why?
|
| Secretory Pathway | 2 | 2009 | 6 | 0.180 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 2 | 2009 | 9 | 0.180 |
Why?
|
| Catheters, Indwelling | 2 | 2010 | 7 | 0.170 |
Why?
|
| Particle Size | 1 | 2019 | 200 | 0.170 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2018 | 1 | 0.170 |
Why?
|
| Proton-Phosphate Symporters | 1 | 2018 | 1 | 0.170 |
Why?
|
| Tetrazolium Salts | 4 | 2011 | 36 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 1998 | 88 | 0.160 |
Why?
|
| Mercaptoethanol | 5 | 2006 | 13 | 0.160 |
Why?
|
| Cytokines | 4 | 2020 | 569 | 0.160 |
Why?
|
| Spleen | 2 | 2011 | 192 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2019 | 490 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 4 | 2004 | 282 | 0.150 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 52 | 0.150 |
Why?
|
| Microarray Analysis | 2 | 2015 | 61 | 0.150 |
Why?
|
| Calcineurin | 2 | 2013 | 21 | 0.150 |
Why?
|
| Blotting, Northern | 3 | 2007 | 139 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 82 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2010 | 342 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2020 | 1802 | 0.140 |
Why?
|
| Receptors, Complement 3d | 1 | 1995 | 3 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 484 | 0.130 |
Why?
|
| Quorum Sensing | 1 | 2015 | 13 | 0.130 |
Why?
|
| Gene Expression | 2 | 2015 | 639 | 0.130 |
Why?
|
| Osteoblasts | 1 | 2015 | 33 | 0.130 |
Why?
|
| Miniaturization | 1 | 2015 | 6 | 0.130 |
Why?
|
| Photochemotherapy | 1 | 2015 | 37 | 0.130 |
Why?
|
| Protein Phosphatase 2 | 1 | 2014 | 22 | 0.130 |
Why?
|
| Cryptococcus gattii | 1 | 2014 | 7 | 0.130 |
Why?
|
| Deoxyribonucleases | 2 | 2011 | 25 | 0.120 |
Why?
|
| Lung Diseases, Fungal | 1 | 2013 | 20 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2018 | 294 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2014 | 56 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2011 | 322 | 0.120 |
Why?
|
| Glycoside Hydrolases | 1 | 2012 | 6 | 0.110 |
Why?
|
| Cryptococcus neoformans | 1 | 2013 | 55 | 0.110 |
Why?
|
| Cyclins | 1 | 2012 | 35 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 106 | 0.110 |
Why?
|
| Epitope Mapping | 2 | 2004 | 31 | 0.110 |
Why?
|
| Fungemia | 2 | 2002 | 3 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2018 | 874 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 1530 | 0.110 |
Why?
|
| Immunoblotting | 3 | 2014 | 170 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2011 | 7 | 0.110 |
Why?
|
| Sodium Hypochlorite | 1 | 2011 | 1 | 0.110 |
Why?
|
| Dental Disinfectants | 1 | 2011 | 1 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2012 | 74 | 0.110 |
Why?
|
| Proteome | 2 | 2013 | 132 | 0.100 |
Why?
|
| Alcohols | 1 | 2011 | 12 | 0.100 |
Why?
|
| Acrylic Resins | 2 | 2009 | 7 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2011 | 901 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 13 | 0.100 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2011 | 20 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1349 | 0.100 |
Why?
|
| Response Elements | 1 | 2011 | 52 | 0.100 |
Why?
|
| Surgical Equipment | 1 | 2010 | 2 | 0.100 |
Why?
|
| Fibrinogen | 2 | 2006 | 23 | 0.100 |
Why?
|
| Tularemia | 1 | 2011 | 114 | 0.100 |
Why?
|
| Francisella tularensis | 1 | 2011 | 115 | 0.100 |
Why?
|
| Chemokines | 1 | 2011 | 89 | 0.100 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2010 | 2 | 0.100 |
Why?
|
| Umbilical Cord | 1 | 2010 | 13 | 0.090 |
Why?
|
| Glycosylation | 2 | 2008 | 92 | 0.090 |
Why?
|
| Silicone Elastomers | 1 | 2009 | 2 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2001 | 73 | 0.090 |
Why?
|
| Phenotype | 5 | 2015 | 650 | 0.090 |
Why?
|
| Vaccination | 2 | 2013 | 259 | 0.090 |
Why?
|
| Denture Bases | 1 | 2009 | 1 | 0.090 |
Why?
|
| Catheterization | 1 | 2009 | 23 | 0.090 |
Why?
|
| Nystatin | 1 | 2009 | 6 | 0.090 |
Why?
|
| Toothbrushing | 1 | 2009 | 8 | 0.090 |
Why?
|
| Porosity | 1 | 2009 | 32 | 0.090 |
Why?
|
| Carbon | 1 | 2010 | 95 | 0.090 |
Why?
|
| Random Allocation | 1 | 2009 | 139 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 445 | 0.090 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 72 | 0.080 |
Why?
|
| Vaccines, Attenuated | 1 | 2009 | 72 | 0.080 |
Why?
|
| Genes, Fungal | 4 | 2008 | 38 | 0.080 |
Why?
|
| Macrophages | 2 | 2020 | 431 | 0.080 |
Why?
|
| Indicators and Reagents | 2 | 2011 | 57 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 298 | 0.080 |
Why?
|
| Formazans | 1 | 2008 | 5 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 1124 | 0.080 |
Why?
|
| Equipment Design | 1 | 2008 | 127 | 0.080 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 69 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2007 | 143 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2009 | 210 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2007 | 80 | 0.080 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2006 | 112 | 0.080 |
Why?
|
| Dentures | 1 | 2006 | 1 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2001 | 161 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2006 | 6 | 0.070 |
Why?
|
| Peptide Mapping | 1 | 2006 | 19 | 0.070 |
Why?
|
| Cell Line | 3 | 2018 | 1289 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2007 | 323 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 383 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 72 | 0.070 |
Why?
|
| Ubiquitins | 2 | 1996 | 45 | 0.070 |
Why?
|
| Rabbits | 4 | 2001 | 278 | 0.070 |
Why?
|
| Tenascin | 1 | 2006 | 6 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 100 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 341 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 550 | 0.070 |
Why?
|
| Laminin | 1 | 2006 | 59 | 0.070 |
Why?
|
| Fibronectins | 1 | 2006 | 65 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2005 | 87 | 0.070 |
Why?
|
| Male | 7 | 2020 | 18870 | 0.070 |
Why?
|
| RNA | 1 | 2007 | 234 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2006 | 119 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 255 | 0.070 |
Why?
|
| Oropharynx | 2 | 2002 | 4 | 0.070 |
Why?
|
| Stomatitis, Denture | 1 | 2004 | 2 | 0.060 |
Why?
|
| Candida tropicalis | 2 | 2019 | 2 | 0.060 |
Why?
|
| Esophagitis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Hemeproteins | 1 | 2004 | 13 | 0.060 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 168 | 0.060 |
Why?
|
| Antigens, Surface | 3 | 2018 | 39 | 0.060 |
Why?
|
| Genes, Viral | 1 | 2003 | 62 | 0.060 |
Why?
|
| Lung | 2 | 2020 | 413 | 0.060 |
Why?
|
| Genotype | 3 | 2002 | 641 | 0.060 |
Why?
|
| Neck | 1 | 2003 | 20 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1999 | 29 | 0.060 |
Why?
|
| Head | 1 | 2003 | 30 | 0.060 |
Why?
|
| Mouth Mucosa | 3 | 2012 | 33 | 0.060 |
Why?
|
| Cell Division | 1 | 2003 | 296 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2002 | 51 | 0.060 |
Why?
|
| Survival Rate | 1 | 2003 | 310 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 173 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2002 | 25 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 186 | 0.050 |
Why?
|
| Cell Communication | 1 | 2002 | 93 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2014 | 406 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2004 | 287 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 416 | 0.050 |
Why?
|
| Plasma | 1 | 2001 | 29 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2001 | 22 | 0.050 |
Why?
|
| Laboratories | 1 | 2001 | 36 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2001 | 23 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 19 | 0.050 |
Why?
|
| Cell Count | 1 | 2001 | 129 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2002 | 183 | 0.050 |
Why?
|
| Middle Aged | 6 | 2005 | 9642 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 70 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 229 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 1999 | 27 | 0.040 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1999 | 33 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 1999 | 52 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 176 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 26 | 0.040 |
Why?
|
| Phosphates | 1 | 2018 | 49 | 0.040 |
Why?
|
| Lasers | 1 | 2018 | 62 | 0.040 |
Why?
|
| Chitosan | 1 | 2018 | 36 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 175 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 217 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 2006 | 310 | 0.040 |
Why?
|
| Drosophila | 1 | 2018 | 133 | 0.040 |
Why?
|
| Karyotyping | 3 | 2002 | 46 | 0.040 |
Why?
|
| Temperature | 2 | 2015 | 275 | 0.040 |
Why?
|
| Niclosamide | 1 | 2016 | 8 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 1998 | 1152 | 0.040 |
Why?
|
| Nanotechnology | 1 | 2018 | 150 | 0.040 |
Why?
|
| Biopolymers | 1 | 1996 | 17 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2016 | 32 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 520 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1996 | 68 | 0.040 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2015 | 17 | 0.040 |
Why?
|
| Protein Binding | 2 | 1996 | 913 | 0.040 |
Why?
|
| Selenium | 1 | 2018 | 144 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1996 | 135 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 1268 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 86 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2015 | 36 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 185 | 0.030 |
Why?
|
| Hydrolases | 2 | 1991 | 14 | 0.030 |
Why?
|
| Solubility | 2 | 1992 | 115 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 77 | 0.030 |
Why?
|
| Microfluidics | 1 | 2015 | 39 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 97 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 2333 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 2013 | 28 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2005 | 219 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 1490 | 0.030 |
Why?
|
| Cells, Immobilized | 1 | 2013 | 2 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 62 | 0.030 |
Why?
|
| Benzethonium | 1 | 2013 | 1 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 87 | 0.030 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2013 | 16 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 135 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2005 | 193 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 129 | 0.030 |
Why?
|
| Biotin | 1 | 1992 | 21 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 528 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 96 | 0.030 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2011 | 3 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 164 | 0.030 |
Why?
|
| Haptoglobins | 1 | 2011 | 9 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 10 | 0.030 |
Why?
|
| Borates | 1 | 2011 | 4 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 2011 | 23 | 0.030 |
Why?
|
| Sulfates | 1 | 2011 | 23 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 2011 | 71 | 0.030 |
Why?
|
| Materials Testing | 1 | 2011 | 71 | 0.030 |
Why?
|
| Adult | 5 | 2005 | 11034 | 0.030 |
Why?
|
| Mycological Typing Techniques | 2 | 2002 | 2 | 0.030 |
Why?
|
| Microspheres | 1 | 1991 | 45 | 0.030 |
Why?
|
| Adsorption | 1 | 1991 | 67 | 0.030 |
Why?
|
| Neutrophils | 1 | 2011 | 124 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 135 | 0.020 |
Why?
|
| Putrescine | 1 | 1990 | 25 | 0.020 |
Why?
|
| Itraconazole | 2 | 2002 | 12 | 0.020 |
Why?
|
| Infant | 2 | 2005 | 1014 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2009 | 13 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2005 | 1318 | 0.020 |
Why?
|
| Secretory Vesicles | 1 | 2009 | 19 | 0.020 |
Why?
|
| Adhesiveness | 1 | 2009 | 5 | 0.020 |
Why?
|
| Shear Strength | 1 | 2009 | 23 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 366 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2002 | 871 | 0.020 |
Why?
|
| Aged | 3 | 2005 | 6448 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 1442 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 286 | 0.020 |
Why?
|
| Mitochondria | 1 | 2011 | 454 | 0.020 |
Why?
|
| Child | 2 | 2005 | 2875 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 47 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 283 | 0.020 |
Why?
|
| Immune Sera | 2 | 1996 | 59 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 185 | 0.020 |
Why?
|
| Mexico | 1 | 2005 | 223 | 0.020 |
Why?
|
| Dioxygenases | 1 | 2004 | 8 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 38 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2004 | 65 | 0.020 |
Why?
|
| Viral Load | 1 | 2005 | 300 | 0.010 |
Why?
|
| Adolescent | 2 | 2005 | 5035 | 0.010 |
Why?
|
| Spain | 1 | 2002 | 33 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 606 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 2002 | 18 | 0.010 |
Why?
|
| Genes, MDR | 1 | 2002 | 2 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 10 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2002 | 8 | 0.010 |
Why?
|
| Blotting, Western | 2 | 1996 | 834 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 223 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 212 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 214 | 0.010 |
Why?
|
| Chromogenic Compounds | 1 | 2001 | 2 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2002 | 82 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 155 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 63 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2001 | 82 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 1425 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 608 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1999 | 15 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1999 | 32 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 105 | 0.010 |
Why?
|
| Incidence | 1 | 2002 | 882 | 0.010 |
Why?
|
| Pharynx | 1 | 1998 | 12 | 0.010 |
Why?
|
| North America | 1 | 1998 | 60 | 0.010 |
Why?
|
| United States | 1 | 2008 | 3894 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 1353 | 0.010 |
Why?
|
| Pyrimidines | 1 | 1998 | 112 | 0.010 |
Why?
|
| Receptors, Laminin | 1 | 1996 | 2 | 0.010 |
Why?
|
| Polyubiquitin | 1 | 1996 | 6 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 35 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 1961 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 175 | 0.010 |
Why?
|
| Antibodies | 1 | 1996 | 135 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 485 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 932 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 3414 | 0.010 |
Why?
|
| Glucan Endo-1,3-beta-D-Glucosidase | 1 | 1992 | 2 | 0.010 |
Why?
|
| Autoradiography | 1 | 1992 | 36 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1992 | 100 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1992 | 100 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1990 | 10 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 195 | 0.010 |
Why?
|